Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors
Cells · 2026
DOI: 10.3390/cells15040373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Jee Young Chung und 6 weiteren Autor:innen. Beteiligte Einrichtung: CHA R&D Institute (CHARI), Seongnam 13488, Republic of Korea. Hauptthemen laut MEDLINE: Killer Cells, Natural, Antibody-Dependent Cell Cytotoxicity, Receptors, Chimeric Antigen, Ovarian Neoplasms. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea (NRF).
Abstract (Originalsprache)
Natural Killer (NK) cell-based immunotherapy relies on CD16-mediated Antibody-Dependent Cellular Cytotoxicity (ADCC), yet the ovarian tumor microenvironment (TME) severely compromises this function via Transforming Growth Factor-beta (TGF-β). This study investigated the molecular mechanisms driving this suppression and evaluated a bi-specific Chimeric Antigen Receptor (CAR) strategy to overcome this hurdle. Primary PBNK cells exposed to TGF-β showed sustained canonical SMAD2 phosphorylation, accompanied by a marked reduction in activating receptors such as CD16 and NKG2D and an increase in exhaustion markers such as PD-1. Functionally, these phenotypic alterations led to failed infiltration and cytotoxicity in vitro and within ovarian cancer-derived spheroids. To overcome this limitation, we engineered NK-92 cells with a bi-specific CAR-targeting Folate Receptor Alpha (FRα) and CD16. While TGF-β typically impairs NK cell function, our armed CAR-NK cells successfully infiltrated tumoroids and synergized with Trastuzumab to induce potent ADCC-mediated lysis. Our findings define the TGF-β/SMAD2 axis as a central driver of NK cell dysfunction in ovarian cancer and demonstrate that bi-specific CAR-NK platforms offer a robust therapeutic solution to bypass TME-induced suppression and restore antibody-mediated tumor suppression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CHA R&D Institute (CHARI), Seongnam 13488, Republic of Korea.
- Department of Biomaterials Engineering, CHA University, 120, Haeryong-ro, Pocheonsi 11160, Republic of Korea.
- Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS UMR 5308, 69007 Lyon, France.
- Université Côte d'Azur, INSERM, C3M, 06204 Nice, France.
- Cha Bundang Medical Center, Cha University School of Medicine, Seongnam 13496, Republic of Korea.
- Department of Physiology, Graduate School of Medicine, CHA University, 120, Haeryong-ro, Pocheonsi 11160, Republic of Korea.
ORCID-Profile: Daseuri Cha, Els Verhoeyen
Förderung
- National Research Foundation of Korea (NRF)
Zitieren
APA
Chung, J. Y., Kim, J. E., Cha, D., Lee, H. J., Verhoeyen, E., An, H. J., & Park, J. E. (2026). Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors. Cells. https://doi.org/10.3390/cells15040373
Vancouver
Chung JY, Kim JE, Cha D, Lee HJ, Verhoeyen E, An HJ, et al. Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors. Cells. 2026. doi:10.3390/cells15040373
BibTeX
@article{Chung2026,
author = {Chung, Jee Young and Kim, Jung Eun and Cha, Daseuri and Lee, Hye Jin and Verhoeyen, Els and An, Hee Jung and Park, Jung Eun},
title = {Engineering Bi-Specific CAR-NK Cells to Restore Antibody-Dependent Cellular Cytotoxicity in Solid Tumors},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15040373}
}
EUVIMED